newsfilter
← Latest News
GlobeNewswire·

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the